Philips proposes new appointment and re-appointments to its Supervisory Board and CEO re-appointment
Royal Philips (NYSE: PHG) proposed the appointment of John DeFord to its Supervisory Board and re-appointments of Paul Stoffels, Herna Verhagen and Sanjay Poonen.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Royal Philips (NYSE: PHG) proposed the appointment of John DeFord to its Supervisory Board and re-appointments of Paul Stoffels, Herna Verhagen and Sanjay Poonen.
Marc Harrison will step down after two terms. The Supervisory Board also reconfirmed the previously announced re-appointment proposal for Roy Jakobs as President/CEO. AGM set for 8 May 2026.
Positive
- John DeFord proposed to join Supervisory Board with deep MedTech and regulatory expertise
- Re-appointment proposals for Paul Stoffels, Herna Verhagen, Sanjay Poonen to retain board continuity
- Supervisory Board proposes re-appointment of Roy Jakobs as President/CEO, signaling leadership continuity
- AGM scheduled for 8 May 2026 to vote on the proposals
Negative
- Departure of Marc Harrison after eight years removes an experienced director from the Supervisory Board
Details
News Market Reaction – PHG
On Mar 23, the day this news came out, PHG closed 2.13% above the previous close.
Data tracked by StockTitan Argus for the Mar 23 session.
Key Figures
- AGM date
- May 8, 2026
- Annual General Meeting 2026 scheduled date
- John DeFord birth year
- 1962
- Year of birth for proposed Supervisory Board member John DeFord
- CEO of Samothrace since
- 2021
- Start year of John DeFord’s CEO role at Samothrace Medical Innovations
- Marc Harrison birth year
- 1964
- Year of birth for outgoing Supervisory Board member Marc Harrison
- Harrison board start
- 2018
- Year Marc Harrison joined Philips’ Supervisory Board
- Roy Jakobs birth year
- 1974
- Year of birth for President/CEO Roy Jakobs proposed for re-appointment
- Progress since
- 2022
- Supervisory Board cites progress made since 2022 under current CEO
- Contact phone
- +31 20 59 77055
- Philips Investor Relations telephone number in release
Historical Context
-
World Oral Health Night campaign highlighting Sonicare plaque removal benefits.
-
Cloud-enabled IntelliSite Pathology Solution added to digital pathology portfolio.
-
Platform-based connected care intelligence highlighted at HIMSS26.
-
Two new Sonicare electric toothbrush ranges and refreshed brand direction.
-
Rembra CT system unveiled with high-speed, high-throughput imaging specs.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
supervisory board financial
board of management financial
non-executive board financial
u.s. fda regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
March 23, 2026
- John DeFord proposed as new member of the Supervisory Board.
- Paul Stoffels, Herna Verhagen and Sanjay Poonen proposed for re-appointment as members of the Supervisory Board.
- Marc Harrison will step down from Philips’ Supervisory Board after his second term.
- Roy Jakobs proposed for re-appointment as President/CEO and Chairman and member of the Board of Management, as previously announced.
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a proposed Supervisory Board appointment and re-appointments, in addition to the previously announced proposal to re-appointment its President/CEO.
The Supervisory Board will submit to the Annual General Meeting of Shareholders 2026 a proposal to appoint John DeFord (American, 1962) as a new member of the Supervisory Board.
The recommendation for this appointment is based on his extensive experience in the medical device industry as a global technology leader and his deep expertise in regulatory affairs, and quality systems, particularly in the US, as well as his strong track record in innovation and product development.
Mr DeFord currently serves as Chairman and Chief Executive Officer of Samothrace Medical Innovations (since 2021). Until 2021, he was Chief Technology Officer at Becton Dickinson, following senior leadership roles at C.R. Bard. He currently holds non-executive board positions at Nordson Corporation, Globus Medical, Inc., Maravai LifeSciences Holdings, Inc., and Enable Injections Inc.
The Supervisory Board will also submit proposals for the re-appointment of Paul Stoffels (Belgian, 1962), Herna Verhagen (Dutch, 1966) and Sanjay Poonen (American, 1969) as members of the Supervisory Board.
These re-appointments will be recommended given the nominees’ valuable contributions to the Supervisory Board and as proven global business leaders with strong track records across medical and health technology, and digital transformation. Their expertise and leadership will remain of great value as Philips continues to advance its strategic priorities, including innovation, patient safety and disciplined execution, to enable better care for more people.
Marc Harrison (American, 1964), whose second term will expire at the end of the AGM 2026, will step down as member of the Supervisory Board. Mr Harrison joined the Supervisory Board in 2018 and has served two consecutive terms.
Mr Feike Sijbesma, Chairman of Philips’ Supervisory Board, said: “On behalf of the Supervisory Board and the Board of Management, I would like to express our sincere gratitude to Marc Harrison for his valuable counsel and contributions over the past eight years. We welcome John DeFord to Philips’ Supervisory Board. He is a highly regarded global technology leader with extensive experience as a senior MedTech executive, bringing interventional domain knowledge and deep expertise in innovation, technical, regulatory, quality, and U.S. FDA matters.
We recommend the re-appointment of Paul Stoffels, Herna Verhagen and Sanjay Poonen, whose continued service and with their exceptional expertise will further strengthen the Supervisory Board. We are grateful for their ongoing commitment and contributions.”
As previously announced on February 10, 2026, Roy Jakobs (Dutch/German, 1974) is proposed by the Supervisory Board to be re-appointed as its President/CEO and Chairman and member of the Board of Management. The proposal to re-appoint Roy Jakobs reflects the Supervisory Board’s recognition of the progress made since 2022 and its confidence in his leadership as Philips enters the next phase of driving profitable growth.
More information about the Annual General Meeting 2026, which will be held on May 8, 2026, will be published later today. Additional information about the Board of Management and the Supervisory Board can be found here.
For further information, please contact:
Michael Fuchs
Philips Global External Relations
Tel.: +31 614869261
E-mail: Michael.Fuchs@philips.com
Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
Attachments
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.